Skip to Main Content

Paper Details

Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLC.
JCO Precis Oncol
3
2018
Author NameAffiliation
Martin L SosAll authors: University Hospital of Cologne Martin L. Sos, University of Cologne
  • 1 - 1

Datasets

Release 1.2